Immunic Inc. Stock
Immunic Inc. Stock
Immunic Inc. took a tumble today and lost -€0.138 (-11.640%).
The stock is an absolute favorite of our community with 25 Buy predictions and no Sell predictions.
Based on the current price of 1.03 € the target price of 8 € shows a potential of 676.7% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Immunic Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | -11.640% | -4.097% | 33.247% | 0.195% | 139.535% | -33.225% | -92.426% |
| NanoViricides Inc. | 0.520% | 20.625% | 19.136% | -11.468% | 3.763% | -15.831% | -77.558% |
| Ocuphire Pharma Inc. | 1.420% | 4.502% | 43.883% | 404.577% | 162.188% | 33.839% | - |
| Actinium Pharmaceuticals Inc. | -0.400% | -3.526% | 4.399% | -11.341% | -18.393% | -88.189% | -87.124% |
Comments
Immunic (IMUX) had its price target lowered by HC Wainwright from $8.00 to $5.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $8.00 to $4.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic to Participate in Investor Conferences in March
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update